Toxoplasmic encephalitis in AIDS-patients before and after the introduction of highly active antiretroviral therapy (HAART)

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 30, Issue 12, 2011, Pages 1521-1525

  Kiderlen, T R ^a   Liesenfeld, O ^a   Schurmann D ^a   Schneider, T ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CLINDAMYCIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; PYRIMETHAMINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SULFONAMIDE;

ADULT; AGED; ARTICLE; AWARENESS; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COMORBIDITY; DEMOGRAPHY; ENCEPHALITIS; FEMALE; GERMANY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; PATIENT COMPLIANCE; PREDICTION; PRIORITY JOURNAL; TOXOPLASMIC ENCEPHALITIS; TOXOPLASMOSIS; TREATMENT OUTCOME;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIPROTOZOAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BERLIN; CD4 LYMPHOCYTE COUNT; CLINDAMYCIN; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PYRIMETHAMINE; RISK FACTORS; SULFONAMIDES; TOXOPLASMOSIS, CEREBRAL; TREATMENT OUTCOME;

EID: 83655192129     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1254-6     Document Type: Article

References (28)

1. JG Montoya O Liesenfeld 2004 Toxoplasmosis Lancet 363 9425 1965 1976 15194258 10.1016/S0140-6736(04)16412-X 1:CAS:528:DC%2BD2cXkvVemuro%3D (Pubitemid 38759657)
2. BJ Luft KG Castro 1991 An overview of the problem of toxoplasmosis and pneumocystosis in AIDS in the USA: implication for future therapeutic trials Eur J Clin Microbiol Infect Dis 10 3 178 181 2060523 10.1007/BF01964455 1:STN:280:DyaK3M3osV2htg%3D%3D
3. WC Mathews SC Fullerton 1994 Use of a clinical laboratory database to estimate Toxoplasma seroprevalence among human immunodeficiency virus-infected patients. Overcoming bias in secondary analysis of clinical records Arch Pathol Lab Med 118 8 807 810 8060230 1:STN:280:DyaK2czjvVamtw%3D%3D (Pubitemid 24249118)
4. N Clumeck 1991 Some aspects of the epidemiology of toxoplasmosis and pneumocystosis in AIDS in Europe Eur J Clin Microbiol Infect Dis 10 3 177 178 2060522 10.1007/BF01964454 1:STN:280:DyaK3M3osV2hsQ%3D%3D
5. A Zumla D Savva RB Wheeler SK Hira NP Luo P Kaleebu SK Sempala JD Johnson R Holliman 1991 Toxoplasma serology in Zambian and Ugandan patients infected with the human immunodeficiency virus Trans R Soc Trop Med Hyg 85 2 227 229 1887478 10.1016/0035-9203(91)90034-V 1:STN:280:DyaK3MzmtFertw%3D%3D
6. N Sacktor RH Lyles R Skolasky C Kleeberger OA Selnes EN Miller JT Becker B Cohen JC McArthur 2001 HIV-associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990-1998 Neurology 56 2 257 260 11160967 1:STN:280:DC%2BD3M7pt1yhuw%3D%3D (Pubitemid 32095372)
7. S Abgrall C Rabaud D Costagliola 2001 Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era Clin Infect Dis 33 10 1747 1755 11595976 10.1086/322622 1:STN:280:DC%2BD3MrmtlWgsA%3D%3D (Pubitemid 33044543)
8. FJ San-Andres R Rubio J Castilla F Pulido G Palao I de Pedro JR Costa A del Palacio 2003 Incidence of acquired immunodeficiency syndrome-associated opportunistic diseases and the effect of treatment on a cohort of 1,115 patients infected with human immunodeficiency virus, 1989-1997 Clin Infect Dis 36 9 1177 1185 12715314 10.1086/374358 (Pubitemid 36549641)
9. JE Kaplan C Benson KH Holmes JT Brooks A Pau H Masur 2009 Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America MMWR Recomm Rep 58 RR-4 1 207 quiz CE201-204
10. A Antinori D Larussa A Cingolani P Lorenzini S Bossolasco MG Finazzi M Bongiovanni G Guaraldi S Grisetti B Vigo B Gigli A Mariano ER Dalle Nogare M De Marco F Moretti P Corsi N Abrescia P Rellecati A Castagna C Mussini A Ammassari P Cinque A d'Arminio Monforte 2004 Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy Clin Infect Dis 39 11 1681 1691 15578371 10.1086/424877 (Pubitemid 39578546)
11. Robert Koch-Institut B (2009) SurvStat. Robert Koch-Institut, Germany
12. Centers for Disease Control and Prevention (CDC) 2010 Prevalence and awareness of HIV infection among men who have sex with men-21 cities, United States, 2008 MMWR Morb Mortal Wkly Rep 59 37 1201 1207
13. L Menendez-Arias 2010 Molecular basis of human immunodeficiency virus drug resistance: an update Antiviral Res 85 1 210 231 19616029 10.1016/j.antiviral.2009.07.006 1:CAS:528:DC%2BC3cXnvFCntA%3D%3D
14. R Paredes B Clotet 2010 Clinical management of HIV-1 resistance Antiviral Res 85 1 245 265 19808056 10.1016/j.antiviral.2009.09.015 1:CAS:528: DC%2BC3cXnvFCnuw%3D%3D
15. B Spire S Duran M Souville C Leport F Raffi JP Moatti 2002 Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach Soc Sci Med 54 10 1481 1496 12061483 10.1016/S0277-9536(01)00125-3 (Pubitemid 34309013)
16. MP Carrieri C Leport C Protopopescu JP Cassuto E Bouvet D Peyramond F Raffi JP Moatti G Chene B Spire 2006 Factors associated with nonadherence to highly active antiretroviral therapy: a 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase J Acquir Immune Defic Syndr 41 4 477 485 16652057 10.1097/01.qai. 0000186364.27587.0e
17. T Kerr A Palepu G Barness J Walsh R Hogg J Montaner M Tyndall E Wood 2004 Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver Antivir Ther 9 3 407 414 15259903 (Pubitemid 38878756)
18. C Protopopescu F Raffi P Roux J Reynes P Dellamonica B Spire C Leport MP Carrieri 2009 Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data J Antimicrob Chemother 64 3 599 606 19602563 10.1093/jac/dkp232 1:CAS:528:DC%2BD1MXhtVWju7jI
19. JE Vidal AV Hernandez AC de Oliveira RF Dauar SP Barbosa Jr R Focaccia 2005 Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era AIDS Patient Care STDs 19 10 626 634 16232047 10.1089/apc.2005.19.626 (Pubitemid 41527673)
20. A Phillips P Pezzotti 2004 Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era AIDS 18 1 51 58 15090829 10.1097/00002030- 200409030-00008 1:STN:280:DC%2BD2c7ptlehsg%3D%3D (Pubitemid 39179631)
21. ML Garly E Petersen C Pedersen JD Lundgren J Gerstoft 1997 Toxoplasmosis in Danish AIDS patients Scand J Infect Dis 29 6 597 600 9571741 10.3109/00365549709035902 1:STN:280:DyaK1c3jtlagsQ%3D%3D
22. NJ Ives BG Gazzard PJ Easterbrook 2001 The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART) in a London clinic J Infect 42 2 134 139 11531320 10.1053/jinf.2001.0810 1:STN:280:DC%2BD3MvovFSqug%3D%3D (Pubitemid 32631815)
23. A Ammassari A Cingolani P Pezzotti DA De Luca R Murri ML Giancola LM Larocca A Antinori 2000 AIDS-related focal brain lesions in the era of highly active antiretroviral therapy Neurology 55 8 1194 1200 11071499 1:STN:280:DC%2BD3crht12qug%3D%3D
24. M Egger M May G Chene AN Phillips B Ledergerber F Dabis D Costagliola A D'Arminio Monforte F de Wolf P Reiss JD Lundgren AC Justice S Staszewski C Leport RS Hogg CA Sabin MJ Gill B Salzberger JA Sterne 2002 Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies Lancet 360 9327 119 129 12126821 10.1016/S0140-6736(02)09411-4 (Pubitemid 34786200)
25. E Girardi CA Sabin AD Monforte 2007 Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing J Acquir Immune Defic Syndr 46 Suppl 1 S3 S8 17713423 10.1097/01.qai.0000286597.57066.2b (Pubitemid 47312320)
26. BJ Luft R Hafner AH Korzun C Leport D Antoniskis EM Bosler DD Bourland 3rd R Uttamchandani J Fuhrer J Jacobson, et al. 1993 Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. Members of the ACTG 077p/ANRS 009 Study Team N Engl J Med 329 14 995 1000 8366923 10.1056/NEJM199309303291403 1:STN:280:DyaK3szns1Smtg%3D%3D (Pubitemid 23307907)
27. RM Levy DE Bredesen ML Rosenblum 1985 Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): experience at UCSF and review of the literature J Neurosurg 62 4 475 495 2983051 10.3171/jns.1985.62.4.0475 1:STN:280:DyaL2M7jtlyqtQ%3D%3D (Pubitemid 15079411)
28. RW Firsching Dieter S Reissberg W Döhring B Peters 2003 Prognostische Bedeutung der MRT bei Bewusstlosigkeit nach Schädel-Hirn- Verletzung Deutsches Ärzteblatt 100 A-1868